Table 3.

Stratified and combined adjusted analysis to determine the impact of the COVID-19 pandemic on viral detectability (a measure of adherence to ART) using multivariable logistic regression.

Type of regimen	ART Start Year	Dispensing interval (Months)						Overall
		One		Three		Six
		OR (95% CI)	P-value	OR (95% CI)	P-value	OR (95% CI)	P-value	OR (95% CI)
TLD/TafED*	< 2019 2019+	Ref 2.51 (1.31, 9.03)	0.012	1 2.38 (0.95, 5.98)	0.064	1 4.75 (3.52, 6.41)	< 0.001	1 4.26 (3.25, 5.58) **
TLE/Atripla*	< 2019 2019+	Ref 1.74 (0.27, 11.30)	0.564	1 7.54(0.49,115.8)	0.147	1 4.67 (2.16, 10.08)	< 0.001	1 4.13 (2.06, 8.29) **
Combined**	< 2019 2019+	Ref 2.97 (1.25, 7.05)	0.014	1 2.63 (1.13, 6.12)	0.025	1 4.62 (3.51, 6.10)	< 0.001	1 4.14 (3.22, 5.31)***

^*Having adjusted for sex, age, CD4, and WHO clinical stage. ^**Adjusted for sex, age, CD4, WHO clinical stage, and the type of first-line ART regimen. ^***Overall estimates between U=U campaign categories while controlling for sex, age, CD4 count, WHO clinical stage, type of first-line regimen, and ART dispensing interval. Refer to Figure 2 for the margins plot of these overall adjusted estimates. TLD (TDF/3TC/DTG): Tenofovir disoproxil fumarate/Lamivudine/Dolutegravir, TafED (TAF/FTC/DTG): Tenofovir alafenamide/Emtricitabine/Dolutegravir, TLE (TDF/3TC/EFV): Tenofovir disoproxil fumarate/Lamivudine/Efavirenz, and Atripla (TDF/FTC/EFV): Tenofovir disoproxil fumarate/Lamivudine/Efavirenz.